Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebo-controlled trial

Christopher J Lettieri; Jacob F Collen; Arn H Eliasson; Timothy M Quast

doi:10.1378/chest.09-0811

Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebo-controlled trial

Chest. 2009 Nov;136(5):1263-1268. doi: 10.1378/chest.09-0811. Epub 2009 Jun 30.

Authors

Christopher J Lettieri¹, Jacob F Collen², Arn H Eliasson³, Timothy M Quast²

Affiliations

¹ Pulmonary, Critical Care & Sleep Medicine, Walter Reed Army Medical Center, Washington, DC; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD. Electronic address: christopher.lettieri@us.army.mil.
² Pulmonary, Critical Care & Sleep Medicine, Walter Reed Army Medical Center, Washington, DC.
³ Pulmonary, Critical Care & Sleep Medicine, Walter Reed Army Medical Center, Washington, DC; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD.

PMID: 19567493
DOI: 10.1378/chest.09-0811

Abstract

Background: The initial experience with continuous positive airway pressure (CPAP) may predict subsequent compliance. In a retrospective study, we found that premedication with nonbenzodiazepine sedative-hypnotic agents during CPAP titration polysomnography independently predicted short-term compliance. To validate these findings, we conducted a prospective clinical trial to assess whether premedication with eszopiclone prior to CPAP titration would improve short-term CPAP compliance.

Methods: Subjects in this randomized, double-blind, placebo-controlled trial received 3 mg of eszopiclone or matching placebo prior to undergoing CPAP titration polysomnography. We compared the quality of CPAP titrations and objective measures of compliance during the first 4 to 6 weeks of therapy between the two groups.

Results: We enrolled 117 subjects, and 98 subjects completed the protocol (eszopiclone, 50 subjects; placebo, 48 subjects). Other than there being more women in the eszopiclone group, the groups were similar at baseline. Compared with placebo, premedication with eszopiclone significantly improved mean (+/- SD) sleep efficiency (87.8 +/- 5.8% vs 80.1 +/- 10.5%, respectively; p = 0.002) and mean total sleep time (350.9 +/- 33.6 min vs 319.7 +/- 48.7 min, respectively; p = 0.007). A trend toward improved sleep latency (19.4 +/- 16.1 min vs 31.8 +/- 30.4 min, respectively; p = 0.08) and the number of residual obstructive events observed at the final CPAP pressure (6.4 +/- 7 events/h vs 12.8 +/- 14.6 events/h, respectively; p = 0.08) during polysomnography was found. Eszopiclone significantly improved CPAP compliance. Among subjects premedicated with eszopiclone, CPAP was used on a higher percentage of nights (75.9 +/- 20.0% vs 60.1 +/- 24.3%, respectively; p = 0.005) and for more hours per night (4.8 +/- 1.5 h vs 3.9 +/- 1.8 h, respectively; p = 0.03).

Conclusions: Premedication with eszopiclone on the night of CPAP titration improved the quality of CPAP titration and led to significantly greater short-term compliance.

Trial registration: ClinicalTrials.gov Identifier: NCT00507117.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Azabicyclo Compounds / therapeutic use*
Combined Modality Therapy
Continuous Positive Airway Pressure / methods*
Double-Blind Method
Eszopiclone
Fatigue
Female
Humans
Hypnotics and Sedatives / therapeutic use*
Male
Middle Aged
Patient Compliance*
Piperazines / therapeutic use*
Placebos

Substances

Azabicyclo Compounds
Hypnotics and Sedatives
Piperazines
Placebos
Eszopiclone

Associated data

ClinicalTrials.gov/NCT00507117